Branded medicines sales clawback cap
STO-REC-STATGMYPTHT2 National
15%
United Kingdom · as of 8 Sep 2026
Branded medicines sales clawback cap in United Kingdom stood at 15% as of 8 September 2026 (ABPI).
- Publisher
- ABPI
- Authority tier
- T2 National
- Locator
- UK competitive weaknesses
- Retrieved
- 17 Sep 2026
- Status
- Verified
What the source says
Despite a new 15 per cent cap on branded medicines sales clawback rates, the UK's rate on newer medicines remains higher than every other comparator country in the analysis, several of which operate no clawback system at all.
Verbatim extraction verified: The figure 15% is directly attested in the quoted passage (UK competitive weaknesses).
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- Association of the British Pharmaceutical Industry. (2026). Green shoots for UK pharma investment, but delivery will decide whether they take root. Retrieved September 17, 2026, from https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Via StatOrigin, https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M
- MLA
- Association of the British Pharmaceutical Industry. "Green shoots for UK pharma investment, but delivery will decide whether they take root." 2026, https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M.
- Chicago
- Association of the British Pharmaceutical Industry. "Green shoots for UK pharma investment, but delivery will decide whether they take root." 2026. https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M.
- BibTeX
- @misc{abpi2026brandedg7t53m, author = {{Association of the British Pharmaceutical Industry}}, title = {Green shoots for UK pharma investment, but delivery will decide whether they take root}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_GMYPTHCR25PSS2A2G385G7T53M}, note = {Original source: https://www.abpi.org.uk/media/news/2026/august/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-root/. Accessed September 17, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Chain of Custody · Verification Audit
Primary Source
- Publisher
- Association of the British Pharmaceutical Industry · homepage ↗
- Authority tier
- Tier 2 · National Official
- Report
- Green shoots for UK pharma investment, but delivery will decide whether they take root
- Type
- Press release
- Published
- —
- Locator
- UK competitive weaknesses
- Retrieved
- 17 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 17 September 2026
- Last revision
- 17 September 2026
- Archival URI
- /stat/stat_GMYPTHCR25PSS2A2G385G7T53M